# CellType: agentic drug discovery around human-biology models

Canonical: https://mudpie.ai/companies/celltype/
Breadcrumb: [Home](https://mudpie.ai/) / [Companies](https://mudpie.ai/companies/) / [CellType: agentic drug discovery around human-biology models](https://mudpie.ai/companies/celltype/)
Author: Ali Abouelatta (https://mudpie.ai/authors/ali-abouelatta/)
Published: 2026-09-19
Updated: 2026-09-19
Research type: Company profile
Method: Company and accelerator sources checked 2026-09-19. Product claims are attributed to their sources; this is research, not a hands-on product trial.

CellType is building an agentic drug company around biological foundation models that simulate human biology. Its intended partner is a pharma or biotech team that wants earlier evidence about targets, toxicity and translation before committing to a long experimental or clinical program.

## What it does

The [YC profile](https://www.ycombinator.com/companies/celltype) says CellType combines AI agents with models of human biology to run the drug-discovery pipeline and is working with Top 10 pharma. The [YC launch](https://www.ycombinator.com/launches/PSn-celltype-the-agentic-drug-company) describes Cell2Sentence, a model that represents cellular biology, and a “virtual human” used for target discovery, toxicity prediction, translational prediction, patient stratification and virtual trials.

CellType says it screened more than 4,000 drugs, predicted a new cancer-treatment signal and validated it in cell lines and intact human tumor microenvironments. Google’s [public write-up](https://blog.google/technology/ai/google-gemma-ai-cancer-therapy-discovery/) is linked from the company’s launch and describes the broader research context. These are company and partner-reported discovery claims, not a clinical result, approved treatment or replacement for human trials.

## Why I’d look closer

The advantage is choosing a human-centered biological model before running every physical experiment. The founder context is unusually strong: David van Dijk is described as a Yale professor who built biological foundation models with Google, while Ivan Vrkic co-developed Cell2Sentence, published at ICML and worked on large-scale model training and CERN software.

The tradeoff is translation. A model can represent more of biology than a simple cell line while still missing dose, delivery, immune response, patient heterogeneity and clinical operations. Drug companies also need to understand which findings are licensed, reproducible and ready for a partner’s validation pipeline.

## What I’d ask

Which predictions have independent wet-lab replication? How does CellType distinguish training data from validation data? What is the model’s performance by indication, population and modality? Can a partner inspect the evidence behind a target or toxicity prediction, and what exactly enters an IND-enabling program?

## My editorial take

Shortlist CellType for a discovery partnership if translational risk is the bottleneck and your team can test the claims against owned assays. Do not treat a virtual human as a clinical substitute. The product earns its value when it changes which experiments get run and those choices hold up outside the model.

## Quick facts

| Field | Sourced detail |
| --- | --- |
| Product | Biological foundation models and AI agents for drug discovery |
| Buyer | Pharma and biotech R&D teams |
| Public evidence | Company reports 4,000-plus drug screening and validated cancer-signal work |
| Pricing | Not published in the checked pages |
| Main question | Does the model improve translational decisions beyond existing preclinical assays? |

## Sources checked

| Source | Checked |
| --- | --- |
| [YC company profile](https://www.ycombinator.com/companies/celltype) | 2026-09-19 |
| [CellType YC launch](https://www.ycombinator.com/launches/PSn-celltype-the-agentic-drug-company) | 2026-09-19 |
| [Google research context](https://blog.google/technology/ai/google-gemma-ai-cancer-therapy-discovery/) | 2026-09-19 |

## Cohort context

CellType is listed in Winter 2026. In our 2026-09-18 directory snapshot, 16 of 199 listed companies in that cohort have YC’s primary industry label Healthcare (8.0%). This is a current-directory comparison, not an original intake count or a performance ranking. [Nine-cohort dataset](https://mudpie.ai/research/yc-cohorts-2026-09-19.json).

## Public website snapshot

Observed 2026-09-19T16:20:06.374Z in raw homepage HTML. This records visible metadata and advertised links, not agent execution or product quality.

| Signal | Homepage observation |
| --- | --- |
| Product description metadata | Not observed in this response |
| Canonical link | Not observed in this response |
| H1 or H2 heading | Not observed in this response |
| Typed structured data | Not observed in this response |
| Docs/developer link | Not observed in this response |
| Pricing link | Not observed in this response |
| llms.txt link | Not observed in this response |
| Markdown alternate | Not observed in this response |

[Public observations](https://mudpie.ai/research/yc-homepage-links-2026-09-19.json) · [Collection method](https://mudpie.ai/research/yc-homepage-methods/README.md). Missing links here do not establish that a capability or file is absent elsewhere.


## Author disclosure

I cofound Lazyweb and publish Mudpie. This is an owner-written publication, not an independent testing organization. Research notes distinguish observations, sourced reporting and editorial judgment.